Dr. Michael J. Strachan is a rheumatologist in Richmond,Virginia. He graduated from Medical College of Virginia Commonwealth University School of Medicine in 1974 and has been in practice for 48 years.
Male
1982655445
| Description | # of Times Performed | # of Patients | Average Charge ($) |
|---|---|---|---|
| Injections of tendon sheath, ligament, or muscle membrane | 112.0 | 74.0 | 95.0 |
| Injections of tendon attachment to bone | 35.0 | 28.0 | 125.0 |
| Injections of trigger points in 1 or 2 muscles | 59.0 | 35.0 | 125.0 |
| Aspiration and/or injection of small joint or joint capsule | 45.0 | 27.0 | 70.0 |
| Aspiration and/or injection of medium joint or joint capsule | 113.0 | 62.0 | 80.0 |
| Aspiration and/or injection of large joint or joint capsule | 344.0 | 161.0 | 95.0 |
| Insertion of needle into vein for collection of blood sample | 841.0 | 396.0 | 12.0 |
| Bone density measurement using dedicated X-ray machine | 92.0 | 92.0 | 185.0 |
| Blood test, comprehensive group of blood chemicals | 1112.0 | 472.0 | 38.0 |
| Manual urinalysis test with examination using microscope | 23.0 | 21.0 | 14.0 |
| Automated urinalysis test | 20.0 | 18.0 | 7.0 |
| Vitamin D-3 level | 182.0 | 164.0 | 61.0 |
| Analysis of substance using immunoassay technique | 36.0 | 18.0 | 24.0 |
| Blood test, thyroid stimulating hormone (TSH) | 20.0 | 19.0 | 35.0 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 1104.0 | 421.0 | 20.0 |
| Red blood cell sedimentation rate, to detect inflammation | 1043.0 | 384.0 | 19.0 |
| Screening test for autoimmune disorder | 22.0 | 21.0 | 25.0 |
| Measurement C-reactive protein for detection of infection or inflammation | 918.0 | 354.0 | 30.0 |
| Measurement of antibody for rheumatoid arthritis assessment | 19.0 | 19.0 | 27.0 |
| Rheumatoid factor level | 18.0 | 18.0 | 12.0 |
| Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 18.0 | 18.0 | 122.0 |
| Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 80.0 | 21.0 | 43.0 |
| Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | 707.0 | 170.0 | 110.0 |
| Infusion of chemotherapy into a vein up to 1 hour | 1177.0 | 179.0 | 365.0 |
| Infusion of chemotherapy into a vein | 272.0 | 45.0 | 80.0 |
| New patient office or other outpatient visit, typically 30 minutes | 29.0 | 29.0 | 155.0 |
| New patient office or other outpatient visit, typically 45 minutes | 42.0 | 42.0 | 230.0 |
| New patient office or other outpatient visit, typically 60 minutes | 61.0 | 61.0 | 290.0 |
| Established patient office or other outpatient visit, typically 15 minutes | 912.0 | 454.0 | 102.87719298 |
| Established patient office or other outpatient, visit typically 25 minutes | 1594.0 | 506.0 | 152.0 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6300.0 | 12.0 | 75.0 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 570.0 | 224.0 | 11.0 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 91420.0 | 21.0 | 12.0 |
| Injection, denosumab, 1 mg | 13920.0 | 145.0 | 27.0 |
| Injection, methylprednisolone acetate, 80 mg | 68.0 | 61.0 | 20.0 |
| Injection, golimumab, 1 mg, for intravenous use | 30050.0 | 32.0 | 35.0 |
| Injection, infliximab, excludes biosimilar, 10 mg | 26760.0 | 77.0 | 119.89715994 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 21.0 | 16.0 | 15.0 |
| Injection, tocilizumab, 1 mg | 142880.0 | 29.0 | 6.9994929311 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 227.0 | 52.0 | 5.0 |
| Injection, zoledronic acid, 1 mg | 85.0 | 17.0 | 100.0 |
| Injection, rituximab, 10 mg | 9400.0 | 28.0 | 135.0 |
Cookies on this website are used to improve your experience and display advertising. You agree to the use of cookies by continuing to use this website. Our Privacy Policy contains more information about how we use cookies.